Mark Schindel
Board Member
Mark brings 25+ years of experience spanning environmental, human and animal health industries, having held leadership positions, including C-level and Board roles in start-ups through larger corporations. Mark has broad, international experience in medical device (Biomet, Zimmer, Tornier), pharmaceutical / biotech (Roche), life-science (Vanderbilt University Tech Transfer) and Government (US DOE/Battelle) sectors. Mark’s expertise spans marketing, sales, brand / product management, project management, R&D, clinical, and business development (M&A, licensing) fields, among others. Specific to medical device, Mark has worked across craniomaxillofacial, pediatrics, plastic surgery, cardiothoracic / cardiovascular, hips, knees, shoulders, foot and ankle and regenerative medicine. Products have ranged from pre-operative technologies, to implants (including biologics, synthetics and xenografts), and delivery technologies (robotics, patient specific instruments, computer assisted surgery, injectables, disposables, etc.). As an entrepreneur, Mark served as CEO, Co-founder, and Board Member for Owl Manor Medical, LLC, an animal heath biologics / medical device company with a focused regenerative medicine portfolio targeting equine and companion animal joint and soft tissue preservation. Following a successful Series A financing round, Owl Manor grew in both revenues and profitability through its globally recognized portfolio. In addition to building a direct US / Canada sales channel, Owl Manor established a successful international business through a combination of distribution and direct sales across Europe, Middle East, Australia, and Mexico. Founded in February of 2015, Owl Manor was acquired on June 1, 2021 by Zoetis, the World’s Largest Animal Health company. Mark holds an MBA from Vanderbilt University and a B.S. with honors from Purdue University.